GlaxoSmithKline (GSK) Q3 EPS Falls to 22.6p; Revs Lower Y/Y
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts GSK Hot Sheet
Join SI Premium – FREE
GlaxoSmithKline (NYSE: GSK) reported Q3 EPS of 22.6 pence, versus 27.2 pence reported last year. Revenue for the quarter came in at GBP6.53 billion, versus GBP7.1 billion reported last year.
For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.
For earnings history and earnings-related data on GlaxoSmithKline (GSK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, Hot EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
